» Articles » PMID: 35203712

Cytoprotective Effect of Idebenone Through Modulation of the Intrinsic Mitochondrial Pathway of Apoptosis in Human Retinal Pigment Epithelial Cells Exposed to Oxidative Stress Induced by Hydrogen Peroxide

Overview
Journal Biomedicines
Date 2022 Feb 25
PMID 35203712
Authors
Affiliations
Soon will be listed here.
Abstract

Idebenone is a ubiquinone short-chain synthetic analog with antioxidant properties, which is believed to restore mitochondrial ATP synthesis. As such, idebenone is investigated in numerous clinical trials for diseases of mitochondrial aetiology and it is authorized as a drug for the treatment of Leber's hereditary optic neuropathy. Mitochondria of retinal pigment epithelium (RPE) are particularly vulnerable to oxidative damage associated with cellular senescence. Therefore, the aim of this study was to explore idebenone's cytoprotective effect and its underlying mechanism. We used a human-RPE cell line (ARPE-19) exposed to idebenone pre-treatment for 24 h followed by conditions inducing HO oxidative damage for a further 24 h. We found that idebenone: (a) ameliorated HO-lowered cell viability in the RPE culture; (b) activated Nrf2 signaling pathway by promoting Nrf2 nuclear translocation; (c) increased Bcl-2 protein levels, leaving unmodified those of Bax, thereby reducing the Bax/Bcl-2 ratio; (d) maintained the mitochondrial membrane potential (ΔΨ) at physiological levels, preserving the functionality of mitochondrial respiratory complexes and counteracting the excessive production of ROS; and (e) reduced mitochondrial cytochrome C-mediated caspase-3 activity. Taken together, our findings show that idebenone protects RPE from oxidative damage by modulating the intrinsic mitochondrial pathway of apoptosis, suggesting its possible role in retinal epitheliopathies associated with mitochondrial dysfunction.

Citing Articles

Evidence for a Functional Link Between the Nrf2 Signalling Pathway and Cytoprotective Effect of S-Petasin in Human Retinal Pigment Epithelium Cells Exposed to Oxidative Stress.

Pizzoferrato M, Lazzarino G, Brancato A, Tabolacci E, Clementi M, Tringali G Antioxidants (Basel). 2025; 14(2).

PMID: 40002367 PMC: 11851853. DOI: 10.3390/antiox14020180.


Different Therapeutic Approaches for Dry and Wet AMD.

Marchesi N, Capierri M, Pascale A, Barbieri A Int J Mol Sci. 2024; 25(23).

PMID: 39684764 PMC: 11641571. DOI: 10.3390/ijms252313053.


The polyphenolic compound punicalagin protects skin fibroblasts from UVA radiation oxidative damage.

Bianchetti G, Bottoni P, Tringali G, Maulucci G, Tabolacci E, Clementi M Curr Res Pharmacol Drug Discov. 2024; 6:100186.

PMID: 38846010 PMC: 11153882. DOI: 10.1016/j.crphar.2024.100186.


Activation of Heme Oxygenase-1 by Mangiferin in Human Retinal Pigment Epithelial Cells Contributes to Blocking Oxidative Damage.

Park C, Cha H, Hwangbo H, Bang E, Kim H, Yun S Biomol Ther (Seoul). 2024; 32(3):329-340.

PMID: 38586992 PMC: 11063488. DOI: 10.4062/biomolther.2023.175.


Protection Activity of 1,4-Naphthoquinones in Rotenone-Induced Models of Neurotoxicity.

Agafonova I, Chingizova E, Chaikina E, Menchinskaya E, Kozlovskiy S, Likhatskaya G Mar Drugs. 2024; 22(2).

PMID: 38393033 PMC: 10890484. DOI: 10.3390/md22020062.


References
1.
Buyse G, Goemans N, Van den Hauwe M, Thijs D, de Groot I, Schara U . Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord. 2011; 21(6):396-405. DOI: 10.1016/j.nmd.2011.02.016. View

2.
Huang Y, Ma M, Zhu X, Li M, Guo M, Liu P . Effectiveness of idebenone nanorod formulations in the treatment of Alzheimer's disease. J Control Release. 2021; 336:169-180. DOI: 10.1016/j.jconrel.2021.06.024. View

3.
Nappi G, Bono G, Merlo P, Denaro A, Proietti R, Martucci N . Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. Arch Gerontol Geriatr. 1992; 15(3):261-9. DOI: 10.1016/0167-4943(92)90061-8. View

4.
Petrillo S, DAmico J, La Rosa P, Bertini E, Piemonte F . Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs. Int J Mol Sci. 2019; 20(20). PMC: 6829337. DOI: 10.3390/ijms20205211. View

5.
Clementi M, Pani G, Sampaolese B, Tringali G . Punicalagin reduces HO-induced cytotoxicity and apoptosis in PC12 cells by modulating the levels of reactive oxygen species. Nutr Neurosci. 2017; 21(6):447-454. DOI: 10.1080/1028415X.2017.1306935. View